Supernus Pharmaceuticals Reports Q2 2026 Results; Confirms Merger with Indivior

What Happened
Supernus Pharmaceuticals, Inc. (SUPN) filed an 8‑K on August 3, 2026 to report its financial results for the quarter ended June 30, 2026 and furnished a press release (Exhibit 99.1) with those results. The filing reiterates that Supernus and Invidior/Indivior Pharmaceuticals have entered a definitive agreement to combine in an all‑stock merger of equals. The companies hosted a joint conference call and webcast on August 3, 2026 at 8:30 a.m. EDT; an investor presentation referenced on the call is available on both companies’ Investor Relations websites and a replay will be posted.

Key Details

• Press release reporting Q2 results for the period ended June 30, 2026 was furnished as Exhibit 99.1 to the 8‑K (filed 2026-08-03).
• Supernus and Invidior/Indivior have a definitive all‑stock merger of equals agreement (previously announced; referenced again in this filing).
• Joint conference call and webcast took place Aug 3, 2026 at 8:30 a.m. EDT; investor presentation referenced in the webcast is available on both companies’ IR sites and a replay will be available.

Why It Matters
Quarterly results give investors the latest data on Supernus’s revenue, expenses and cash flow trends; the press release/exhibit is the primary source for the specific financial figures and management commentary. The announced all‑stock merger of equals with Indivior is a material corporate transaction that could affect Supernus’s scale, product portfolio and future financial profile. Investors should review the press release and the investor presentation (and listen to the webcast replay) for the detailed numbers and management discussion before making decisions.